FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2270462887> ?p ?o ?g. }

• W2270462887 endingPage "55" @default.
• W2270462887 startingPage "48" @default.
• W2270462887 abstract "Transplantation of mobilized allogeneic peripheral blood stem cells (PBSC) has recently been reported by several groups. However, few patients receiving an allograft in the early stage of their disease have been described so far.Fifteen patients with early stage hematologic malignancies were transplanted with cryopreserved allogeneic PBSC from HLA-identical siblings. PBSC were collected after priming with 10 micrograms/kg/day of glycosylated granulocyte colony-stimulating factor (G-CSF, lenograstim). Outcomes were compared to a historical control group of 15 patients who received conventional bone marrow transplantation (BMT) from HLA-identical sibling donors. The two groups were matched for diagnosis, stage of disease, age, preparative regimen, graft-versus host (GVHD) prophylaxis, patients' and donors' gender and cytomegalovirus (CMV) serology. Diagnoses in both groups were: chronic myelogenous leukemia (CML) in first chronic phase (= 5), acute leukemia in first complete remission (CR) (= 5), non-Hodgkin's lymphoma in CR (= 1) and multiple myeloma (MM) with sensitive disease (= 4). All patients were given cyclosporin-A (CsA) and methotrexate (MTX) for GVHD prophylaxis. Preparative regimens varied according to diagnosis and included either busulfan/cyclophosphamide combination (BU/Cy) or total body irradiation/cyclophosphamide +/- melphalan (TBI/Cy +/- Mel).The patients in the PBSC group showed a more rapid hematopoietic reconstitution with a significant difference in the median times to 1 x 10(9) neutrophils/L (19 days vs. 26 days; p = 0.03) and to platelet transfusion independence (18 days versus 22 days; p = 0.02). This finding was associated with a significantly shorter hospitalization (28 days versus 33 days after transplantation; p = 0.01). In the PBSC series, grade II-IV acute GVHD occurred in 3 patients (20%) and grade III-IV in 1 patient (7%). In the BMT control group, grade II-IV aGVHD was reported in 2 cases (13%; p = NS) and 1 case had grade III-IV GVHD. Chronic GVHD developed in 7 patients (47%) (limited = 6; extensive = 1) undergoing PBSC transplantation and 5 patients (33%) (limited = 4; extensive = 1) in the BMT series (p = NS). No difference was found in the incidence of grade II-IV (according to the World Health Organization) mucositis, whereas PBSC recipients did have a significantly lower incidence of additional severe (grade III-IV) organ toxicity. After a median follow-up of 300 days (range 180-630), all PBSC patients are still alive with a median Karnofsky score of 100% (range 80%-100%). Thirteen patients are in CR and 2 myeloma patient are in good partial remission (PR). Also, in the BMT group the peritransplant mortality was absent; two MM patients died due to progressive disease at day +796 and +1,023, respectively; one leukemic patient died of chronic GVHD 407 days after transplantation and one additional leukemic individual relapsed 1,140 days after BMT.This retrospective comparison suggests that allogeneic PBSC transplantation performed in the early stage of the disease is safe and may be associated with a more rapid hematopoietic reconstitution than BMT, as well as lower transplant-related toxicity and earlier hospital discharge with apparently no increased risk of acute and chronic GVHD." @default.
• W2270462887 created "2016-06-24" @default.
• W2270462887 creator A5009003698 @default.
• W2270462887 creator A5013901146 @default.
• W2270462887 creator A5018987163 @default.
• W2270462887 creator A5029836748 @default.
• W2270462887 creator A5033359713 @default.
• W2270462887 creator A5044939975 @default.
• W2270462887 creator A5055149081 @default.
• W2270462887 creator A5055349649 @default.
• W2270462887 creator A5056071879 @default.
• W2270462887 creator A5059892449 @default.
• W2270462887 creator A5067915047 @default.
• W2270462887 creator A5070577986 @default.
• W2270462887 creator A5071926851 @default.
• W2270462887 creator A5072253025 @default.
• W2270462887 creator A5078220223 @default.
• W2270462887 creator A5079336756 @default.
• W2270462887 date "1998-01-01" @default.
• W2270462887 modified "2023-09-23" @default.
• W2270462887 title "Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation." @default.
• W2270462887 cites W1491993932 @default.
• W2270462887 cites W1544569979 @default.
• W2270462887 cites W1555387300 @default.
• W2270462887 cites W1570247268 @default.
• W2270462887 cites W190201512 @default.
• W2270462887 cites W1934171667 @default.
• W2270462887 cites W1962483565 @default.
• W2270462887 cites W1983916012 @default.
• W2270462887 cites W2006204311 @default.
• W2270462887 cites W2093687787 @default.
• W2270462887 cites W2155683936 @default.
• W2270462887 cites W2237667700 @default.
• W2270462887 cites W2240289126 @default.
• W2270462887 cites W2261855117 @default.
• W2270462887 cites W2262982217 @default.
• W2270462887 cites W2271876496 @default.
• W2270462887 cites W2337052966 @default.
• W2270462887 cites W2339471373 @default.
• W2270462887 cites W2394770057 @default.
• W2270462887 cites W2406667691 @default.
• W2270462887 cites W2409164440 @default.
• W2270462887 cites W2417748698 @default.
• W2270462887 cites W2417849984 @default.
• W2270462887 cites W2477069154 @default.
• W2270462887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9542323" @default.
• W2270462887 hasPublicationYear "1998" @default.
• W2270462887 type Work @default.
• W2270462887 sameAs 2270462887 @default.
• W2270462887 citedByCount "7" @default.
• W2270462887 countsByYear W22704628872021 @default.
• W2270462887 crossrefType "journal-article" @default.
• W2270462887 hasAuthorship W2270462887A5009003698 @default.
• W2270462887 hasAuthorship W2270462887A5013901146 @default.
• W2270462887 hasAuthorship W2270462887A5018987163 @default.
• W2270462887 hasAuthorship W2270462887A5029836748 @default.
• W2270462887 hasAuthorship W2270462887A5033359713 @default.
• W2270462887 hasAuthorship W2270462887A5044939975 @default.
• W2270462887 hasAuthorship W2270462887A5055149081 @default.
• W2270462887 hasAuthorship W2270462887A5055349649 @default.
• W2270462887 hasAuthorship W2270462887A5056071879 @default.
• W2270462887 hasAuthorship W2270462887A5059892449 @default.
• W2270462887 hasAuthorship W2270462887A5067915047 @default.
• W2270462887 hasAuthorship W2270462887A5070577986 @default.
• W2270462887 hasAuthorship W2270462887A5071926851 @default.
• W2270462887 hasAuthorship W2270462887A5072253025 @default.
• W2270462887 hasAuthorship W2270462887A5078220223 @default.
• W2270462887 hasAuthorship W2270462887A5079336756 @default.
• W2270462887 hasConcept C126322002 @default.
• W2270462887 hasConcept C141071460 @default.
• W2270462887 hasConcept C2776364478 @default.
• W2270462887 hasConcept C2776694085 @default.
• W2270462887 hasConcept C2776755627 @default.
• W2270462887 hasConcept C2776960273 @default.
• W2270462887 hasConcept C2777408962 @default.
• W2270462887 hasConcept C2778461978 @default.
• W2270462887 hasConcept C2778496288 @default.
• W2270462887 hasConcept C2778880498 @default.
• W2270462887 hasConcept C2780611847 @default.
• W2270462887 hasConcept C2911091166 @default.
• W2270462887 hasConcept C71924100 @default.
• W2270462887 hasConcept C90924648 @default.
• W2270462887 hasConceptScore W2270462887C126322002 @default.
• W2270462887 hasConceptScore W2270462887C141071460 @default.
• W2270462887 hasConceptScore W2270462887C2776364478 @default.
• W2270462887 hasConceptScore W2270462887C2776694085 @default.
• W2270462887 hasConceptScore W2270462887C2776755627 @default.
• W2270462887 hasConceptScore W2270462887C2776960273 @default.
• W2270462887 hasConceptScore W2270462887C2777408962 @default.
• W2270462887 hasConceptScore W2270462887C2778461978 @default.
• W2270462887 hasConceptScore W2270462887C2778496288 @default.
• W2270462887 hasConceptScore W2270462887C2778880498 @default.
• W2270462887 hasConceptScore W2270462887C2780611847 @default.
• W2270462887 hasConceptScore W2270462887C2911091166 @default.
• W2270462887 hasConceptScore W2270462887C71924100 @default.
• W2270462887 hasConceptScore W2270462887C90924648 @default.
• W2270462887 hasIssue "1" @default.
• W2270462887 hasLocation W22704628871 @default.

• next